Peer-influenced content. Sources you trust. No registration required. This is HCN.

ReachMDThe Emerging Role of HER2 (ERBB2) Mutations in NSCLC

HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Drs. Lyudmila Bazhenova and Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice in this 15-minute CME activity.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form